APA (7th ed.) Citation

J, S., M, M., J, I., HA, A., S, L., G, B., . . . CD, D. (2023). A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood cancer journal, 13(1), 101. https://doi.org/10.1038/s41408-023-00871-1

Chicago Style (17th ed.) Citation

J, Senapati, et al. "A Phase I Study of Milademetan (DS3032b) in Combination with Low Dose Cytarabine with or Without Venetoclax in Acute Myeloid Leukemia: Clinical Safety, Efficacy, and Correlative Analysis." Blood Cancer Journal 13, no. 1 (2023): 101. https://doi.org/10.1038/s41408-023-00871-1.

MLA (9th ed.) Citation

J, Senapati, et al. "A Phase I Study of Milademetan (DS3032b) in Combination with Low Dose Cytarabine with or Without Venetoclax in Acute Myeloid Leukemia: Clinical Safety, Efficacy, and Correlative Analysis." Blood Cancer Journal, vol. 13, no. 1, 2023, p. 101, https://doi.org/10.1038/s41408-023-00871-1.